Author Correction: IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial

作者：Lukas Bunse, Katharina A.M. Lindner, Antje Wick, Angelika Freitag, Lisa-Marie Lanz, Dominic Edelmann, Abigail Suwala, M Breckwoldt, Inga Harting, Felix Sahm, Richard F. Schlenk, A Schmitt, Oliver Schnell, J. Hense, Martin Misch, Dietmar Krex, Monika Denk, Juliane S. Walz, J. P. Steinbach, Andreas von Deimling, Michael Schmitt, Theresa Bunse, Ghazaleh Tabatabai, Martin Bendszus, Isabel Poschke, Wolfgang Wick, Michael Platten · 发表于：Nature Cancer · 年份：2026 · DOI：10.1038/s43018-026-01227-x · 研究领域：Medicine、Pediatrics、Internal medicine、Medical physics、Intensive care medicine、Surgery

In the version of the article initially published, in the Abstract, the sentence “The 8-year progression-free and overall survival (OS) rates were 0.42 months (confidence interval (CI): 0.24–0.59) and 0.66 months (CI: 0.46–0.79), respectively” should have read “The 8-year progression-free and overall survival (OS) rates were 0.42 (confidence interval (CI): 0.24–0.59) and 0.66 (CI: 0.46–0.79), respectively”. This correction has been made to the HTML and PDF versions of the article.